Mexico on Friday approved the anti-viral drug remdesivir for emergency use treating COVID-19 patients in the Latin American country, one of the worst hit by the pandemic.
Regulatory agency Cofepris said it had authorized the medicine for use exclusively by hospitals and specialist doctors during the early stages of the illness.
Mexico joins other countries including the United States, Canada and Japan, as well as the European Commission, that have approved the treatment for use against the coronavirus.
Remdesivir, made by US pharma giant Gilead, was one of the first drugs to show relative promise in shortening the time to recovery in some COVID-19 patients.
But its efficacy in reducing the mortality rate is unproven.
A World Health Organization-backed study said in October that the drug had “little or no effect” on COVID mortality.
Mexico, a country of 126 million people, has recorded more than 193,000 known COVID-19 deaths—the world’s third-highest toll.
© 2021 AFP
Mexico authorizes remdesivir to treat COVID (2021, March 13)
retrieved 5 February 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.